ALIZAYVE Trademark
ALIZAYVE is a USPTO trademark filed by Bristol-Myers Squibb Company. Status: Pending.
Prosecution Summary
Trademark Summary
The standard character mark ALIZAYVE covers pharmaceutical preparations for treating obesity, cardiovascular diseases, cancer, inflammatory diseases, and other medical conditions in International Class 005, along with goods and services in domestic classes 006, 018, 044, 046, 051, and 052. It is owned by Bristol-Myers Squibb Company, a Delaware corporation based in Princeton, New Jersey. A Notice of Allowance was issued on December 2, 2025, requiring the applicant to file a Statement of Use or extension request within six months; no oppositions or legal proceedings are present.
Recent Activity
The application was filed on April 8, 2025, approved for publication on September 4, 2025, and published for opposition in the USPTO Official Gazette on Oct
Trademark Facts
| Mark | ALIZAYVE |
|---|---|
| Serial Number | 99126295 |
| Status | Pending |
| Filing Date | 2025-04-08 |
| Mark Type | Word |
| Nice Classes | 005 (Pharmaceuticals) |
| Owner | Bristol-Myers Squibb Company |
| Attorney of Record | Marilyn F. Kelly |
| Prosecution Events | 9 |
| Latest Event | NOAM on 2025-12-02 |
Goods & Services
Pharmaceutical preparations for the treatment and prevention of obesity, cardiovascular diseases, central nervous system diseases, metabolic disorders, stroke, cancer, inflammatory diseases, respiratory diseases, infectious diseases, auto-immune diseases, solid organ transplant rejection, autoinflammatory disease, blood disease, multiple sclerosis, ulcerative colitis, cystic fibrosis, arthritis, and musculoskeletal and skin disease; Antivirals; Antibodies for medical purposes; Biological preparations for the treatment of cancer; Anticoagulants; Stem cells for medical purposes; Radiopharmaceutical preparations for the treatment of cancer and solid tumors; Diagnostic radiopharmaceutical preparations; Diagnostic preparations for medical purposes